Insider · CIK 0001392029

Davis Todd C

Reports to the SEC for 5 companies · JUPITER, FL

sec.gov

Transactions

Companies

Filings

CIK

0001392029

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-06-30	LGNDLIGAND PHARMACEUTICALS INCJ Other	Director, Chief Executive Officer	JOther	+132 sh	$160.71	+$21.2K	199,513
2026-06-11	PTHSPelthos Therapeutics Inc.P Purchase	Director	PPurchase	+35.4K sh	$27.80	+$986K	75,331
2026-06-11	PTHSPelthos Therapeutics Inc.P Purchase	Director	PPurchase	+503 sh	$28.73	+$14.4K	75,834
2026-06-10	PVLAPALVELLA THERAPEUTICS, INC. · Stock Option (Right to Buy)A Award	Director	AAward	+3,000 sh	—	—	3,000
2026-03-02	LGNDLIGAND PHARMACEUTICALS INCA Award	Director, Chief Executive Officer	AAward	+10.5K sh	—	—	199,381
2026-03-02	LGNDLIGAND PHARMACEUTICALS INC · Employee Stock Option (right to buy)A Award	Director, Chief Executive Officer	AAward	+50.1K sh	—	—	50,058
2026-02-15	LGNDLIGAND PHARMACEUTICALS INCF Tax Payment	Director, Chief Executive Officer	FTax Payment	−2,805 sh	$183.83	−$516K	188,886
2026-02-15	LGNDLIGAND PHARMACEUTICALS INCF Tax Payment	Director, Chief Executive Officer	FTax Payment	−2,039 sh	$183.83	−$375K	195,946
2026-02-15	LGNDLIGAND PHARMACEUTICALS INCF Tax Payment	Director, Chief Executive Officer	FTax Payment	−4,255 sh	$183.83	−$782K	191,691
2026-02-14	LGNDLIGAND PHARMACEUTICALS INCF Tax Payment	Director, Chief Executive Officer	FTax Payment	−15.6K sh	$183.83	−$2.87M	197,985
2026-02-14	LGNDLIGAND PHARMACEUTICALS INCF Tax Payment	Director, Chief Executive Officer	FTax Payment	−8,178 sh	$183.83	−$1.5M	173,941
2026-02-14	LGNDLIGAND PHARMACEUTICALS INCA Award	Director, Chief Executive Officer	AAward	+39.6K sh	—	—	213,585
2026-02-14	LGNDLIGAND PHARMACEUTICALS INCA Award	Director, Chief Executive Officer	AAward	+20.8K sh	—	—	182,119
2025-12-04	LGNDLIGAND PHARMACEUTICALS INCG Gift	Director, Chief Executive Officer	GGift	−130 sh	—	—	161,337
2025-07-02	PTHSPelthos Therapeutics Inc.A Award	Director	AAward	+19.1K sh	—	—	39,886
2025-07-02	PTHSPelthos Therapeutics Inc. · Stock OptionA Award	Director	AAward	+58.2K sh	—	—	58,230
2025-07-02	PTHSPelthos Therapeutics Inc. · Restricted Stock UnitsA Award	Director	AAward	+19.1K sh	—	—	36,969
2025-07-01	PTHSPelthos Therapeutics Inc. · Series A Convertible Preferred StockC Conversion	Director	CConversion	−15K sh	—	—	3,000
2025-07-01	PTHSPelthos Therapeutics Inc. · Series A Convertible Preferred StockJ Other	Director	JOther	+31.3K sh	—	—	3,127,868
2025-07-01	PTHSPelthos Therapeutics Inc.C Conversion	Director	CConversion	+1.5M sh	$10.00	+$15M	1,500,000
2025-06-30	LGNDLIGAND PHARMACEUTICALS INCJ Other	Director, Chief Executive Officer	JOther	+233 sh	$91.08	+$21.2K	161,467
2025-06-10	PVLAPALVELLA THERAPEUTICS, INC. · Non-Qualified Stock Option (right to buy)A Award	Director	AAward	+12.4K sh	—	—	12,350
2025-05-09	LGNDLIGAND PHARMACEUTICALS INCP Purchase	Director, Chief Executive Officer	PPurchase	+1,680 sh	$104.57	+$176K	153,404
2025-05-09	LGNDLIGAND PHARMACEUTICALS INCP Purchase	Director, Chief Executive Officer	PPurchase	+5,523 sh	$105.67	+$584K	161,234
2025-05-09	LGNDLIGAND PHARMACEUTICALS INCP Purchase	Director, Chief Executive Officer	PPurchase	+2,307 sh	$104.53	+$241K	155,711
2025-03-04	LGNDLIGAND PHARMACEUTICALS INC · Employee Stock Option (right to buy)A Award	Director, Chief Executive Officer	AAward	+93.5K sh	—	—	93,476
2025-03-04	LGNDLIGAND PHARMACEUTICALS INCA Award	Director, Chief Executive Officer	AAward	+21.4K sh	—	—	151,724
2025-02-15	LGNDLIGAND PHARMACEUTICALS INCF Tax Payment	Director, Chief Executive Officer	FTax Payment	−4,255 sh	$120.00	−$511K	130,342
2025-02-15	LGNDLIGAND PHARMACEUTICALS INCF Tax Payment	Director, Chief Executive Officer	FTax Payment	−2,231 sh	$120.00	−$268K	134,597
2025-02-14	LGNDLIGAND PHARMACEUTICALS INCA Award	Director, Chief Executive Officer	AAward	+20.8K sh	—	—	143,794
2025-02-14	LGNDLIGAND PHARMACEUTICALS INCF Tax Payment	Director, Chief Executive Officer	FTax Payment	−6,966 sh	$120.00	−$836K	136,828
2024-12-13	PVLAPALVELLA THERAPEUTICS, INC. · Stock Option (right to buy)A Award	Director	AAward	+24.7K sh	—	—	24,700
2024-11-13	PTHSPelthos Therapeutics Inc.A Award	Director	AAward	+4,961 sh	—	—	20,778
2024-08-08	LGNDLIGAND PHARMACEUTICALS INCP Purchase	Director, Chief Executive Officer	PPurchase	+2,500 sh	$97.39	+$243K	123,010
2024-06-28	LGNDLIGAND PHARMACEUTICALS INCJ Other	Director, Chief Executive Officer	JOther	+350 sh	$60.71	+$21.2K	120,510
2024-06-14	PTHSPelthos Therapeutics Inc.A Award	Director	AAward	+12.9K sh	—	—	15,817
2024-06-14	PTHSPelthos Therapeutics Inc. · Restricted Stock UnitsA Award	Director	AAward	+129K sh	—	—	213,701
2024-03-25	LGNDLIGAND PHARMACEUTICALS INC · Non-Qualified Stock Option (right to buy)M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	−2,156 sh	—	—	0
2024-03-25	LGNDLIGAND PHARMACEUTICALS INC · Non-Qualified Stock Option (right to buy)M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	−2,855 sh	—	—	0
2024-03-25	LGNDLIGAND PHARMACEUTICALS INC · Non-Qualified Stock Option (right to buy)M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	−3,556 sh	—	—	0
2024-03-25	LGNDLIGAND PHARMACEUTICALS INC · Non-Qualified Stock Option (right to buy)M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	−7,448 sh	—	—	0
2024-03-25	LGNDLIGAND PHARMACEUTICALS INCM Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	+3,556 sh	$66.19	+$235K	120,160
2024-03-25	LGNDLIGAND PHARMACEUTICALS INCM Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	+2,156 sh	$68.51	+$148K	116,604
2024-03-25	LGNDLIGAND PHARMACEUTICALS INCM Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	+2,855 sh	$67.24	+$192K	114,448
2024-03-25	LGNDLIGAND PHARMACEUTICALS INCM Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	+7,448 sh	$46.20	+$344K	111,593
2024-02-27	LGNDLIGAND PHARMACEUTICALS INC · Employee Stock Option (right to buy)A Award	Director, Chief Executive Officer	AAward	+132K sh	—	—	131,723
2024-02-27	LGNDLIGAND PHARMACEUTICALS INCA Award	Director, Chief Executive Officer	AAward	+32.4K sh	—	—	104,145
2024-02-21	PTHSPelthos Therapeutics Inc. · Secured Convertible Promissory NoteC Conversion	Director	CConversion	—	—	—	0
2024-02-21	PTHSPelthos Therapeutics Inc.M Exercise/Conversion	Director	MExercise/Conversion	+29.2K sh	$4.80	+$140K	29,167
2024-02-15	LGNDLIGAND PHARMACEUTICALS INCF Tax Payment	Director, Chief Executive Officer	FTax Payment	−1,381 sh	$74.65	−$103K	71,709

Recent filings

Accepted (ET)
Jul 64
Davis Todd C0002001011-26-000106
SEC(opens sec.gov)
Jun 154
Davis Todd C0001919246-26-000088
SEC(opens sec.gov)
Jun 124
Davis Todd C0001104659-26-073426
SEC(opens sec.gov)
Apr 14/A
Davis Todd C0001919246-26-000046
SEC(opens sec.gov)
Mar 274
Davis Todd C0002001011-26-000033
SEC(opens sec.gov)
Feb 184
Davis Todd C0002001011-26-000011
SEC(opens sec.gov)
Dec 84
Davis Todd C0002001011-25-000121
SEC(opens sec.gov)
Jul 74
Davis Todd C0001753926-25-001105
SEC(opens sec.gov)
Jul 34
Davis Todd C0001753926-25-001075
SEC(opens sec.gov)

Companies

Address

555 HERITAGE DRIVE SUITE 200

JUPITER, FL, 33458